Laura Baglietto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6316461/publications.pdf

Version: 2024-02-01

194 papers 15,994 citations

65 h-index 21843 118 g-index

200 all docs

200 docs citations

200 times ranked 22460 citing authors

#	Article	IF	CITATIONS
1	Can the computed tomography texture analysis of colorectal liver metastases predict the response to first-line cytotoxic chemotherapy?. World Journal of Hepatology, 2022, 14, 244-259.	0.8	6
2	Associations between plasma levels of brominated flame retardants and methylation of DNA from peripheral blood: A cross-sectional study in a cohort of French women. Environmental Research, 2022, 210, 112788.	3.7	3
3	COVID-19 Infection Among Incarcerated Individuals and Prison Staff in Lombardy, Italy, March 2020 to February 2021. JAMA Network Open, 2022, 5, e224862.	2.8	6
4	Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease, 2022, 54, 1367-1373.	0.4	10
5	Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks. International Journal of Environmental Research and Public Health, 2022, 19, 6799.	1.2	1
6	Remote Working and Home Learning: How the Italian Academic Population Dealt with Changes Due to the COVID-19 Pandemic Lockdown. Sustainability, 2022, 14, 8161.	1.6	8
7	Thymomaâ€associated myasthenia gravis : Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thoracic Cancer, 2021, 12, 106-113.	0.8	13
8	Novel mammogramâ€based measures improve breast cancer risk prediction beyond an established mammographic density measure. International Journal of Cancer, 2021, 148, 2193-2202.	2.3	18
9	Alcohol consumption is associated with widespread changes in blood DNA methylation: Analysis of crossâ€sectional and longitudinal data. Addiction Biology, 2021, 26, e12855.	1.4	49
10	Psychological distress in the academic population and its association with socio-demographic and lifestyle characteristics during COVID-19 pandemic lockdown: Results from a large multicenter Italian study. PLoS ONE, 2021, 16, e0248370.	1.1	26
11	Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case–control study nested within the French E3N cohort. British Journal of Cancer, 2021, 124, 1734-1743.	2.9	27
12	Telomere Length and Male Fertility. International Journal of Molecular Sciences, 2021, 22, 3959.	1.8	18
13	Use of antiseizure medications and safety of branded versus generic formulations: A comparative study on Tuscan administrative databases. Epilepsy and Behavior, 2021, 117, 107876.	0.9	3
14	Causal mediation analysis in presence of multiple mediators uncausally related. International Journal of Biostatistics, 2021, 17, 191-221.	0.4	25
15	Association between telomere length and mitochondrial copy number and cancer risk in humans: A meta-analysis on more than 300,000 individuals. Critical Reviews in Oncology/Hematology, 2021, 167, 103510.	2.0	13
16	Myeloid neoplasms and autoimmune diseases: markers of association. Clinical and Experimental Rheumatology, 2021, , .	0.4	4
17	Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study. Journal of Clinical Medicine, 2021, 10, 5743.	1.0	3
18	Adiposity and estrogen receptorâ€positive, postmenopausal breast cancer risk: Quantification of the mediating effects of fasting insulin and free estradiol. International Journal of Cancer, 2020, 146, 1541-1552.	2.3	15

#	Article	IF	CITATIONS
19	Smoking and blood DNA methylation: an epigenome-wide association study and assessment of reversibility. Epigenetics, 2020, 15, 358-368.	1.3	56
20	Interval breast cancer risk associations with breast density, family history and breast tissue aging. International Journal of Cancer, 2020, 147, 375-382.	2.3	22
21	Stochastic Epigenetic Mutations Are Associated with Risk of Breast Cancer, Lung Cancer, and Mature B-cell Neoplasms. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2026-2037.	1.1	18
22	Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. Frontiers in Oncology, 2020, 10, 1428.	1.3	36
23	HCV microâ€elimination in two prisons in Milan, Italy: A model of care. Journal of Viral Hepatitis, 2020, 27, 1444-1454.	1.0	18
24	Invasive Pneumococcal Disease in Tuscany Region, Italy, 2016–2017: Integrating Multiple Data Sources to Investigate Underreporting. International Journal of Environmental Research and Public Health, 2020, 17, 7581.	1.2	3
25	The CoV-2 outbreak: how hematologists could help to fight Covid-19. Pharmacological Research, 2020, 157, 104866.	3.1	36
26	Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Alimentary Pharmacology and Therapeutics, 2020, 52, 284-291.	1.9	41
27	Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. British Journal of Clinical Pharmacology, 2020, 86, 1296-1305.	1.1	30
28	Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women. International Journal of Cancer, 2020, 147, 1306-1314.	2.3	17
29	Appraising the causal relevance of DNA methylation for risk of lung cancer. International Journal of Epidemiology, 2019, 48, 1493-1504.	0.9	53
30	Genomeâ€wide association study of peripheral blood DNA methylation and conventional mammographic density measures. International Journal of Cancer, 2019, 145, 1768-1773.	2.3	17
31	Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. Breast Cancer Research, 2019, 21, 68.	2.2	31
32	Blood DNA methylation and breast cancer risk: a meta-analysis of four prospective cohort studies. Breast Cancer Research, 2019, 21, 62.	2.2	34
33	Maternal educational inequalities in measured body mass index trajectories in three European countries. Paediatric and Perinatal Epidemiology, 2019, 33, 226-237.	0.8	17
34	Epigenome-wide association study for lifetime estrogen exposure identifies an epigenetic signature associated with breast cancer risk. Clinical Epigenetics, 2019, 11, 66.	1.8	21
35	Breast Cancer Risk After Recent Childbirth. Annals of Internal Medicine, 2019, 170, 22.	2.0	120
36	Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Breast Cancer Research, 2018, 20, 29.	2.2	44

#	Article	IF	Citations
37	Identifying and correcting epigenetics measurements for systematic sources of variation. Clinical Epigenetics, 2018, 10, 38.	1.8	29
38	Mutational and epigenetic signatures in cancer tissue linked to environmental exposures and lifestyle. Current Opinion in Oncology, 2018, 30, 61-67.	1.1	16
39	Association of DNA Methylation-Based Biological Age With Health Risk Factors and Overall and Cause-Specific Mortality. American Journal of Epidemiology, 2018, 187, 529-538.	1.6	106
40	Antiâ€Mýllerian hormone and risk of ovarian cancer in nine cohorts. International Journal of Cancer, 2018, 142, 262-270.	2.3	5
41	Cirrus: An Automated Mammography-Based Measure of Breast Cancer Risk Based on Textural Features. JNCI Cancer Spectrum, 2018, 2, pky057.	1.4	24
42	Predicting interval and screen-detected breast cancers from mammographic density defined by different brightness thresholds. Breast Cancer Research, 2018, 20, 152.	2.2	24
43	Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. JAMA Oncology, 2018, 4, e181771.	3.4	210
44	Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. BMC Cancer, 2018, 18, 171.	1.1	75
45	Longitudinal Study of Mammographic Density Measures That Predict Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 651-660.	1.1	36
46	Genomeâ€Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Caseâ€Control Study. Prostate, 2017, 77, 471-478.	1.2	31
47	A metabolomic study of biomarkers of meat and fish intake ,. American Journal of Clinical Nutrition, 2017, 105, 600-608.	2.2	156
48	DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility. European Journal of Cancer, 2017, 75, 299-307.	1.3	154
49	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724.	5.8	106
50	The Premenopausal Breast Cancer Collaboration: A Pooling Project of Studies Participating in the National Cancer Institute Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1360-1369.	1.1	23
51	Demographic, lifestyle, and other factors in relation to antim $\tilde{A}^{1}\!/\!$ llerian hormone levels in mostly late premenopausal women. Fertility and Sterility, 2017, 107, 1012-1022.e2.	0.5	43
52	25-Hydroxyvitamin D concentration and all-cause mortality: the Melbourne Collaborative Cohort Study. Public Health Nutrition, 2017, 20, 1775-1784.	1.1	7
53	Tumor characteristics and family history in relation to mammographic density and breast cancer: The French E3N cohort. Cancer Epidemiology, 2017, 49, 156-160.	0.8	13
54	Social adversity and epigenetic aging: a multi-cohort study on socioeconomic differences in peripheral blood DNA methylation. Scientific Reports, 2017, 7, 16266.	1.6	181

#	Article	IF	CITATIONS
55	DNA methylation changes measured in preâ€diagnostic peripheral blood samples are associated with smoking and lung cancer risk. International Journal of Cancer, 2017, 140, 50-61.	2.3	115
56	Mammographic density and risk of breast cancer by tumor characteristics: a case-control study. BMC Cancer, 2017, 17, 859.	1.1	5
57	Long-Term Exposure to Ambient Air Pollution and Incidence of Postmenopausal Breast Cancer in 15 European Cohorts within the ESCAPE Project. Environmental Health Perspectives, 2017, 125, 107005.	2.8	104
58	Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women. Journal of Clinical Oncology, 2017, 35, 3230-3239.	0.8	13
59	Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the <scp>E3Nâ€EPIC</scp> cohort. International Journal of Cancer, 2016, 138, 2415-2427.	2.3	37
60	Mammographic density and risk of breast cancer by mode of detection and tumor size: a case-control study. Breast Cancer Research, 2016, 18, 63.	2.2	30
61	Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. JAMA Oncology, 2016, 2, 1295.	3.4	285
62	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Research, 2016, 76, 5103-5114.	0.4	100
63	Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour. Breast Cancer Research and Treatment, 2016, 160, 173-180.	1.1	6
64	Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested caseâ€control study in nonsmoking postmenopausal women from the ⟨scp⟩EPIC⟨/scp⟩ cohort. International Journal of Cancer, 2016, 138, 1129-1138.	2.3	21
65	Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prevention Research, 2016, 9, 758-765.	0.7	41
66	Change in weight and waist circumference and risk of colorectal cancer: results from the Melbourne Collaborative Cohort Study. BMC Cancer, 2016, 16, 157.	1.1	24
67	A treelet transform analysis to relate nutrient patterns to the risk of hormonal receptor-defined breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutrition, 2016, 19, 242-254.	1.1	26
68	An epidemiological model for prediction of endometrial cancer risk in Europe. European Journal of Epidemiology, 2016, 31, 51-60.	2.5	43
69	Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case–Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 127-134.	1.1	27
70	Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms. Epigenomics, 2016, 8, 55-66.	1.0	35
71	Vegetable and fruit consumption and the risk of hormone receptor–defined breast cancer in the EPIC cohort. American Journal of Clinical Nutrition, 2016, 103, 168-177.	2.2	48
72	Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies. International Journal of Epidemiology, 2016, 45, 916-928.	0.9	101

#	Article	IF	Citations
73	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
74	Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2015, 136, 399-410.	2.3	36
75	Investigation of geneâ€environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. International Journal of Cancer, 2015, 136, E685-96.	2.3	34
76	Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study. Breast Cancer Research, 2015, 17, 49.	2.2	30
77	Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies. BMC Research Notes, 2015, 8, 543.	0.6	15
78	Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clinical Epigenetics, 2015, 7, 67.	1.8	95
79	Reproductive and hormoneâ€related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. International Journal of Cancer, 2015, 137, 1196-1208.	2.3	53
80	Hypomethylation of smoking-related genes is associated with future lung cancer in four prospective cohorts. Nature Communications, 2015, 6, 10192.	5.8	197
81	Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. British Journal of Cancer, 2015, 113, 1622-1631.	2.9	29
82	Pre-diagnostic polyphenol intake and breast cancer survival: the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Breast Cancer Research and Treatment, 2015, 154, 389-401.	1.1	31
83	Alcohol intake and breast cancer in the <scp>E</scp> uropean prospective investigation into cancer and nutrition. International Journal of Cancer, 2015, 137, 1921-1930.	2.3	65
84	Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 951-961.	1.1	51
85	A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort. Breast Cancer Research and Treatment, 2015, 150, 415-426.	1.1	10
86	Dietary Intake of Acrylamide and Epithelial Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 291-297.	1.1	16
87	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Research, 2015, 75, 2457-2467.	0.4	55
88	Baseline and lifetime alcohol consumption and risk of differentiated thyroid carcinoma in the EPIC study. British Journal of Cancer, 2015, 113, 840-847.	2.9	20
89	Healthy lifestyle and risk of breast cancer among postmenopausal women in the <scp>E</scp> uropean <scp>P</scp> rospective <scp>I</scp> nvestigation into <scp>C</scp> ancer and <scp>N</scp> utrition cohort study. International Journal of Cancer, 2015, 136, 2640-2648.	2.3	95
90	A Genome-Wide "Pleiotropy Scan―Does Not Identify New Susceptibility Loci for Estrogen Receptor Negative Breast Cancer. PLoS ONE, 2014, 9, e85955.	1.1	8

#	Article	IF	CITATIONS
91	Change in Body Size and Mortality: Results from the Melbourne Collaborative Cohort Study. PLoS ONE, 2014, 9, e99672.	1.1	25
92	Association between Melanocytic Nevi and Risk of Breast Diseases: The French E3N Prospective Cohort. PLoS Medicine, 2014, 11, e1001660.	3.9	12
93	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	1.5	39
94	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	5.8	16
95	Additive Interactions Between Susceptibility Single-Nucleotide Polymorphisms Identified in Genome-Wide Association Studies and Breast Cancer Risk Factors in the Breast and Prostate Cancer Cohort Consortium. American Journal of Epidemiology, 2014, 180, 1018-1027.	1.6	36
96	Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Research and Treatment, 2014, 148, 665-673.	1.1	93
97	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	1.4	53
98	Post-GWAS gene–environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79 000 women. Human Molecular Genetics, 2014, 23, 5260-5270.	1.4	37
99	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	2.2	97
100	Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> Cancer Research, 2014, 74, 852-861.	0.4	48
101	Prolactin Determinants in Healthy Women: A Large Cross-Sectional Study within the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2532-2542.	1.1	10
102	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	1.4	32
103	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	1.8	23
104	Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status-Results from the EPIC cohort. International Journal of Cancer, 2014, 134, 1947-1957.	2.3	71
105	ldentification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Geneâ€Environment Interactions. Genetic Epidemiology, 2014, 38, 84-93.	0.6	28
106	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	1.3	145
107	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nature Communications, 2014, 5, 5303.	5.8	109
108	Associations of Mammographic Dense and Nondense Areas and Body Mass Index With Risk of Breast Cancer. American Journal of Epidemiology, 2014, 179, 475-483.	1.6	48

#	Article	IF	CITATIONS
109	Mammographic Density Phenotypes and Risk of Breast Cancer: A Meta-analysis. Journal of the National Cancer Institute, 2014, 106, .	3.0	261
110	Dietary fat intake and risk of epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology, 2014, 38, 528-537.	0.8	16
111	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	1.4	12
112	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	2.2	14
113	The use of DNA from archival dried blood spots with the Infinium HumanMethylation450 array. BMC Biotechnology, 2013, 13, 23.	1.7	62
114	Dietary intake of B vitamins and methionine and breast cancer risk. Cancer Causes and Control, 2013, 24, 1555-1563.	0.8	41
115	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
116	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	2.6	98
117	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
118	The impact of missing data on analyses of a time-dependent exposure in a longitudinal cohort: a simulation study. Emerging Themes in Epidemiology, 2013, 10, 6.	1.2	17
119	Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant. Breast Cancer Research and Treatment, 2013, 138, 543-548.	1.1	10
120	Dietary Intake of B Vitamins and Methionine and Colorectal Cancer Risk. Nutrition and Cancer, 2013, 65, 659-667.	0.9	41
121	Fruit and Vegetable Intake and Risk of Breast Cancer by Hormone Receptor Status. Journal of the National Cancer Institute, 2013, 105, 219-236.	3.0	164
122	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	2.6	201
123	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	9.4	374
124	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
125	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome–wide interaction study. Endocrine-Related Cancer, 2013, 20, 875-887.	1.6	26
126	Evidence of Geneâ€"Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	1.5	136

#	Article	IF	Citations
127	Associations between Weight in Early Adulthood, Change in Weight, and Breast Cancer Risk in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1409-1416.	1.1	40
128	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
129	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	5.8	98
130	Population-Based Estimate of Prostate Cancer Risk for Carriers of the HOXB13 Missense Mutation G84E. PLoS ONE, 2013, 8, e54727.	1.1	31
131	Common Breast Cancer Susceptibility Variants in <i>LSP1</i> and <i>RAD51L1</i> Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1156-1166.	1.1	101
132	19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.4	100
133	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancerâ€"Specific Death, and Increased Risk of a Second Breast Cancer. Journal of Clinical Oncology, 2012, 30, 4308-4316.	0.8	162
134	The role of genetic breast cancer susceptibility variants as prognostic factors. Human Molecular Genetics, 2012, 21, 3926-3939.	1.4	80
135	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	9.4	256
136	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1783-1791.	1.1	17
137	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	1.4	168
138	A review of the reporting and handling of missing data in cohort studies with repeated assessment of exposure measures. BMC Medical Research Methodology, 2012, 12, 96.	1.4	119
139	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	1.1	11
140	Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. American Journal of Clinical Nutrition, 2012, 95, 713-725.	2.2	92
141	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	1.1	35
142	Weight change and prostate cancer incidence and mortality. International Journal of Cancer, 2012, 131, 1711-1719.	2.3	70
143	Dietary intake of B vitamins and methionine and prostate cancer incidence and mortality. Cancer Causes and Control, 2012, 23, 855-863.	0.8	37
144	The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. Breast Cancer Research and Treatment, 2012, 131, 347-350.	1.1	6

#	Article	IF	Citations
145	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
146	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	1.1	27
147	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	3.0	596
148	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	1.4	152
149	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	9.4	279
150	FAN1 variants identified in multiple-case early-onset breast cancer families via exome sequencing: no evidence for association with risk for breast cancer. Breast Cancer Research and Treatment, 2011, 130, 1043-1049.	1.1	16
151	Alcohol consumption and risk of glioblastoma; evidence from the Melbourne collaborative cohort study. International Journal of Cancer, 2011, 128, 1929-1934.	2.3	40
152	Associations of common variants at $1p11.2$ and $14q24.1$ (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ \in . Human Molecular Genetics, 2011, 20, 4693-4706.	1.4	71
153	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. Journal of Medical Genetics, 2011, 48, 698-702.	1.5	5
154	The rs12975333 variant in the miR-125a and breast cancer risk in Germany, Italy, Australia and Spain. Journal of Medical Genetics, 2011, 48, 703-704.	1.5	13
155	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 2011, 71, 6240-6249.	0.4	109
156	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research, 2010, 12, R110.	2.2	82
157	Physical activity, body size and composition, and risk of ovarian cancer. Cancer Causes and Control, 2010, 21, 2183-2194.	0.8	36
158	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
159	Body Size, Weight Change, and Risk of Colon Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2978-2986.	1.1	67
160	Asthma, Asthma Medications, and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2318-2324.	1.1	27
161	Circulating Steroid Hormone Levels and Risk of Breast Cancer for Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 492-502.	1.1	94
162	Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 22231-22236.	3.3	249

#	Article	IF	CITATIONS
163	Missense Variants in <i>ATM</i> in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2143-2151.	1.1	33
164	Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers. Journal of the National Cancer Institute, 2010, 102, 193-201.	3.0	328
165	Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. PLoS Medicine, 2010, 7, e1000279.	3.9	764
166	Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor–Negative Breast Cancer Survival. Journal of the National Cancer Institute, 2010, 102, 650-662.	3.0	48
167	A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Research, 2010, 12, R109.	2.2	102
168	Association of ESR1 gene tagging SNPs with breast cancer risk. Human Molecular Genetics, 2009, 18, 1131-1139.	1.4	84
169	Risk of Estrogen Receptor–Positive and –Negative Breast Cancer and Single–Nucleotide Polymorphism 2q35-rs13387042. Journal of the National Cancer Institute, 2009, 101, 1012-1018.	3.0	99
170	Dietary Patterns and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3126-3129.	1.1	48
171	The effect of socioeconomic status on survival from colorectal cancer in the Melbourne Collaborative Cohort Study. Social Science and Medicine, 2009, 68, 290-297.	1.8	38
172	Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Research and Treatment, 2009, 115, 171-179.	1.1	113
173	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	9.4	434
174	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	9.4	276
175	Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1610-1616.	1.1	57
176	Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Research and Treatment, 2008, 108, 57-67.	1.1	59
177	The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations. Gastroenterology, 2008, 135, 419-428.e1.	0.6	480
178	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. PLoS Genetics, 2008, 4, e1000054.	1.5	315
179	Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 763-768.	1.1	93
180	Cancer Risks For Mismatch Repair Gene Mutation Carriers: A Population-Based Early Onset Case-Family Study. Clinical Gastroenterology and Hepatology, 2006, 4, 489-498.	2.4	151

#	Article	IF	Citations
181	Segregation analysis of urothelial cell carcinoma. European Journal of Cancer, 2006, 42, 1428-1433.	1.3	30
182	Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. Journal of Clinical Epidemiology, 2006, 59, 114-124.	2.4	89
183	Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer. Breast Cancer Research and Treatment, 2006, 98, 167-172.	1.1	7
184	Alcohol consumption and prostate cancer risk: Results from the Melbourne collaborative cohort study. International Journal of Cancer, 2006, 119, 1501-1504.	2.3	33
185	AVERAGE VOLUME OF ALCOHOL CONSUMED, TYPE OF BEVERAGE, DRINKING PATTERN AND THE RISK OF DEATH FROM ALL CAUSES. Alcohol and Alcoholism, 2006, 41, 664-671.	0.9	45
186	A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1914-1919.	1.1	31
187	Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study. BMJ: British Medical Journal, 2005, 331, 807.	2.4	77
188	Effect of the Synthetic Retinoid Fenretinide on Circulating Free Prostate-Specific Antigen, Insulin-Like Growth Factor Binding Protein-3 Levels in Men with Superficial Bladder Cancer. Clinical Cancer Research, 2005, 11, 2083-2088.	3.2	6
189	A Two-by-Two Factorial Trial Comparing Oral with Transdermal Estrogen Therapy and Fenretinide with Placebo on Breast Cancer Biomarkers. Clinical Cancer Research, 2004, 10, 4389-4397.	3.2	26
190	Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Research and Treatment, 2004, 88, 63-73.	1.1	25
191	AfterhMSH2 andhMLH1?what next? Analysis of three-generational, population-based, early-onset colorectal cancer families. International Journal of Cancer, 2002, 102, 166-171.	2.3	43
192	Autosomal dominant inheritance of prostate cancer: a confirmatory study. Urology, 2001, 57, 97-101.	0.5	47
193	Epidemiology of Prostate Cancer. European Urology, 2001, 39, 2-3.	0.9	10
194	Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. Journal of Cellular Biochemistry, 2000, 76, 311-321.	1.2	10